NERV
NASDAQ · Biotechnology
Minerva Neurosciences Inc
$5.55
+0.12 (+2.21%)
Open$5.47
Previous Close$5.43
Day High$5.84
Day Low$5.41
52W High$12.46
52W Low$1.57
Volume—
Avg Volume182.5K
Market Cap191.48M
P/E Ratio—
EPS$-29.10
SectorBiotechnology
Analyst Ratings
Buy
9 analysts
Price Target
-27.4% upside
Current
$5.55
$5.55
Target
$4.03
$4.03
$3.03
$4.03 avg
$5.66
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.71M | 21.78M | 21.76M |
| Net Income | 4.38M | 3.81M | 4.44M |
| Profit Margin | 20.2% | 17.5% | 20.4% |
| EBITDA | 6.15M | 6.17M | 6.37M |
| Free Cash Flow | 3.82M | 4.48M | 4.63M |
| Rev Growth | +1.1% | -8.2% | +18.1% |
| Debt/Equity | 0.50 | 0.50 | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |